TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20191258
Drug: Nutritional formulation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional formulation (NF) consisting of folic acid, B12, Vitamin E, S‐adenosylmethionine, N‐acetyl cysteine, and Acetyl‐L‐carnitine
Study: 20191258
Drug: Nutritional formulation
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional formulation (NF)
Study: 9397080
Drug: Ketoprofen 200
Normalized name: ketoprofen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 200 mg once daily
Study: 30157924
Drug: 32 mg
Normalized name: caffeine 32 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 mg buprenorphine
Study: 30157924
Drug: 64 mg
Normalized name: sulfur 64 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 64 mg buprenorphine
Study: 30157924
Drug: 96 mg
Normalized name: camphor 96 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 96 mg buprenorphine
Study: 26362831
Drug: Nebivolol (beta-blocker)
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebivolol (beta-blocker)
Study: 26362831
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (20 mg nebivolol/320 mg valsartan)
Study: 17604930
Drug: Low-attenuation barium
Normalized name: barium
DrugBank: Barium (DB12481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-attenuation barium sulphate suspension
Study: 17604930
Drug: High-attenuation barium
Normalized name: barium
DrugBank: Barium (DB12481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-attenuation barium sulphate preparation
Study: 16451158
Drug: FFP (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: FFP (10 ml/kg)
Study: 1437922
Drug: Intravenous pamidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pamidronate (60 mg infusion over 2 hours)
Study: 1437922
Drug: Intravenous pamidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pamidronate (infusions over 4, 8, or 24 hours)
Study: 1437922
Drug: Intravenous pamidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pamidronate (various infusion rates)
Study: 1437922
Drug: Intravenous pamidronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pamidronate (short infusions)
Study: 28819922
Drug: Therapist-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-delivered cognitive behavior therapy/motivational interviewing (CBT/MI)
Study: 25908605
Drug: Oral S-1
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral S-1 plus cisplatin (80 mg/m2/day on days 1-21 plus cisplatin 60 mg/m2 on day 8 every 4-5 weeks)
Study: 25908605
Drug: Docetaxel plus
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel plus cisplatin (60 mg/m2 on day 1 plus cisplatin 80 mg/m2 on day 1 every 3-4 weeks)
Study: 17345837
Drug: fexofenadine 180
Normalized name: fexofenadine 180 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: fexofenadine 180 mg
Study: 17345837
Drug: desloratadine 5
Normalized name: desloratadine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: desloratadine 5 mg
Study: 14570783
Drug: Inhalation anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation anaesthesia using sevoflurane
Study: 10781481
Drug: Chloroprocaine (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroprocaine (4.5 mg/kg)
Study: 8635674
Drug: 100 mmol/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mmol/day sodium supplement (group 2)
Study: 2580168
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oxprenolol plus diuretic
Study: 2580168
Drug: Captopril plus
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril plus diuretic
Study: 26351927
Drug: Enteral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral melatonin (6 mg total: 3 mg loading dose at 9 pm + six 0.5 mg doses hourly)
Study: 26351927
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered using a similar regimen to melatonin)
Study: 24732894
Drug: Argatroban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argatroban (10 mg intravenous twice daily for 2 days before and 3 days after stenting)
Study: 15314593
Drug: Parent-administered visual
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-administered visual acuity testing using the EVA (Group A)
Study: 11269893
Drug: Miglitol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglitol (25 to 100 mg trice daily for 24 weeks)
Study: 9017770
Drug: Enalapril-diltiazem ER
Normalized name: diltiazem / enalapril Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril-diltiazem ER (dosage titrated to response, maximum of enalapril 10 mg-diltiazem ER 360 mg/day)
Study: 9017770
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg-diltiazem ER 120 mg once/day (titrated to response)
Study: 30681971
Drug: Melissa officinalis
Normalized name: melissa officinalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melissa officinalis L. based product (MO), 500 mg capsules, 2 capsules daily for 3 months
Study: 24163425
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection (control) during exercise
Study: 17760599
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% imiquimod cream used daily in conjunction with laser therapy
Study: 17760599
Drug: Placebo used
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo used daily in conjunction with laser therapy
Study: 7781653
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g ascorbic acid (AA) and 0.2 g pantothenic acid (PA) supplementation
Study: 27412664
Drug: Usual routine
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual routine treatment with exercise training (n=44)
Study: 27412664
Drug: Usual routine
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual routine treatment without training (n=20)
Study: 26099752
Drug: Epidural injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injection of 80 mg triamcinolone and 8 ml bupivacaine 0.25%
Study: 26099752
Drug: Epidural injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injection of 8 ml bupivacaine 0.25%
Study: 23747802
Drug: Combined inpatient
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined inpatient physical training (aerobic + strength) for the duration of neoadjuvant chemotherapy, 3 weekly 60-70 min exercise sessions
Study: 15577047
Drug: Raroxifene treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raroxifene treatment
Study: 9924277
Drug: Tomato purée
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato purée (16.5 mg total lycopene)
Study: 9924277
Drug: Fresh raw
Normalized name: Potassium/Wheat Germ 250 MG Oral Powder [NATURFRESH RAW WHEAT GERM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh raw tomato (16.5 mg total lycopene)
Study: 9924277
Drug: Daily dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dietary portions of tomato purée (16.5 mg total lycopene) for 7 days
Study: 9924277
Drug: Daily dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dietary portions of fresh raw tomato (16.5 mg total lycopene) for 7 days
Study: 2682096
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g mezlocillin and 0.5 g metronidazole (one-shot dose)
Study: 782698
Drug: BCNU maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCNU maintenance therapy
Study: 22230353
Drug: 6% carbohydrate‐electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% carbohydrate‐electrolyte solution (CHO)
Study: 22230353
Drug: Electrolyte solution
Normalized name: electrolyte solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrolyte solution (PL)
Study: 20049949
Drug: pH-dependent release
Normalized name: PH-284
DrugBank: PH-284 (DB05452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH-dependent release formulation of mesalamine at 2.4 g/day
Study: 20049949
Drug: Time-dependent release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-dependent release formulation of mesalamine at 2.25 g/day
Study: 20049949
Drug: pH-dependent release
Normalized name: PH-284
DrugBank: PH-284 (DB05452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH-dependent release formulation of mesalamine
Study: 20049949
Drug: Time-dependent release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-dependent release formulation of mesalamine
Study: 19265453
Drug: artesunate monotherapy
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: artesunate monotherapy 7 d (AS7)
Study: 12093428
Drug: Glutamine-supplemented total
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine-supplemented total parenteral nutrition
Study: 15613202
Drug: Conventional pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pharmacotherapy
Study: 31899379
Drug: Salvadora persica
Normalized name: SALVADORA PERSICA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvadora persica (SP) gel application
Study: 31899379
Drug: Professionally administered
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professionally administered plaque removal (PAPR)
Study: 26159015
Drug: Qingfei Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingfei Decoction (QD) treatment group
Study: 24631099
Drug: Automated reminder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated reminder messages for vaccine doses two and three
Study: 23066765
Drug: Discharge Preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discharge Preparation Program (DPP)
Study: 19776405
Drug: Escalated dose
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalated dose of daunorubicin (90 mg/m²) plus cytarabine (200 mg/m² for 7 days)
Study: 19776405
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose of daunorubicin (45 mg/m²) plus cytarabine (200 mg/m² for 7 days)
Study: 17096464
Drug: Both cognitive-behavioral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both cognitive-behavioral group therapy and clinical case management
Study: 12631177
Drug: Enamel matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enamel matrix proteins (EMP) treatment
Study: 11085964
Drug: Acetylcholine (intra-arterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcholine (intra-arterial infusion)
Study: 11085964
Drug: Verapamil (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (calcium channel blocker)
Study: 8857879
Drug: Indwelling percutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indwelling percutaneous intramuscular electrode composed of helically coiled Teflon‐coated rope stranded from 19 hard drawn wires of SUS 316L stainless steel (SES 114)
Study: 8857879
Drug: Indwelling percutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indwelling percutaneous intramuscular electrode
Study: 1352732
Drug: Esmolol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (2 or 3 mg.kg-1)
Study: 1352732
Drug: Esmolol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (3 mg.kg-1)
Study: 1352732
Drug: Esmolol and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol and topical laryngeal anaesthesia
Study: 30361250
Drug: Sertraline 25‐100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 25‐100 mg (titrated upwards over 9 days)
Study: 28916591
Drug: Computer-guided glucose
Normalized name: ACCU-CHEK GUIDE (GLUCOSE) METER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-guided glucose infusion rate (GIR) with continuous glucose monitoring (CGM)
Study: 25792176
Drug: Magnesium 30
Normalized name: Magnesium 30mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium 30 mg/kg
Study: 23385272
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection plus physiotherapy
Study: 19483418
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose of docetaxel (40 or 50 mg/m²)
Study: 19483418
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of docetaxel (60 mg/m²)
Study: 17089233
Drug: Lornoxicam 8
Normalized name: lornoxicam 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam 8 mg i.v. at the end of the operation followed by 8 mg b.i.d., i.v. for 24 hours
Study: 16283275
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg oral gemfibrozil twice daily for 2 days
Study: 16283275
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg oral gemfibrozil
Study: 8432299
Drug: Captopril 6.25
Normalized name: captopril 6.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 6.25 mg every 6 h on the first day and 12.5 mg qid on the second day if MAP > or = 70 mmHg (group 1)
Study: 22738092
Drug: Total intravenous-plus-oral
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous-plus-oral regimen (LEV)
Study: 22738092
Drug: Total intravenous-plus-oral
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous-plus-oral regimen (PHT)
Study: 21705281
Drug: Bevacizumab 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 7.5 or 15 mg/kg intravenously (I.V.) on day 1, every 21 days plus investigator's choice of agents (pemetrexed, docetaxel, or erlotinib) for second-line and subsequent lines of treatment.
Study: 21705281
Drug: Investigator's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice of agents alone indicated for use in second-line and subsequent lines of treatment, but no further bevacizumab treatment.
Study: 18562414
Drug: Citalopram (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (selective serotonin reuptake inhibitor)
Study: 12922956
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy including glucocorticoids
Study: 12922956
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (2001 cohort with early RA)
Study: 8638787
Drug: Ketorolac 60
Normalized name: ketorolac 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 60 mg IV 15 min after skin incision
Study: 1999742
Drug: Counseling plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counseling plus prescription of nicotine-containing gum (Nicorette)
Study: 31504608
Drug: 500 IU
Normalized name: Vitamin E 500 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 IU per steer daily (MED)
Study: 31504608
Drug: 1,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 IU per steer daily (HIGH)
Study: 30133134
Drug: Cinnamyl Isobutyrate
Normalized name: isostearyl isobutyrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamyl Isobutyrate (CIB) 0.45 mg in 75 g glucose solution
Study: 30133134
Drug: Control (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (75 g glucose solution)
Study: 23185753
Drug: Fuzheng Jianpi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzheng Jianpi Decoction (FJD) combined with chemotherapy
Study: 12297711
Drug: Thermal balloon
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal balloon endometrial ablation therapy
Study: 7602060
Drug: Interferon-alpha 2a
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha 2a (IFN-alpha 2a) at an induction dose of 6 MIU thrice weekly for 3 months, followed by 3 MIU thrice weekly for an additional 3 months as maintenance therapy.
Study: 227340
Drug: Long-acting fluphenazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting fluphenazine decanoate with social therapy (ST)
Study: 227340
Drug: Oral fluphenazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluphenazine hydrochloride
Study: 11417777
Drug: 4-mg gum
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-mg gum
Study: 9327189
Drug: soluble aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: soluble aspirin
Study: 9327189
Drug: plain aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: plain aspirin
Study: 9327189
Drug: enteric-coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: enteric-coated aspirin granules
Study: 9327189
Drug: mouth-dispersible aspirin
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mouth-dispersible aspirin
Study: 3259087
Drug: Propofol 1
Normalized name: propofol 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1 mg/kg intravenous bolus for induction and 0.1 mg/kg/minute continuous infusion for maintenance
Study: 3259087
Drug: Ketamine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 1.5 mg/kg intravenous bolus for induction and 50 micrograms/kg/minute continuous infusion for maintenance
Study: 22297
Drug: Pindolol administered
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pindolol administered before bronchoscopy
Study: 21452932
Drug: Combined endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined endocrine therapy and radiotherapy
Study: 19728936
Drug: Epidural Steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural Steroid Injections (80 mg of methylprednisolone with 3 ml of 2% plain xylocaine and 3 ml of normal saline)
Study: 19728936
Drug: Conservative management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative management (bed rest, non-steroidal anti-inflammatory agents, muscle relaxants, and opioids)
Study: 8648369
Drug: Epirubicin doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin doses >60 mg/m2
Study: 8648369
Drug: Epirubicin doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin doses
Study: 1523876
Drug: MDP‐virosome vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDP‐virosome vaccine
Study: 8034508
Drug: HA vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA vaccine
Study: 28010050
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg of intravenous iron isomaltoside
Study: 19803232
Drug: J in
Normalized name: IOTROLAN 240MG/ML INJ INTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: J in three‐needle therapy
Study: 10788542
Drug: CPH 82
Normalized name: CETYLPYRIDINIUM CHLORIDE 1.11 g in 13.0 mL TOPICAL SPRAY [CPH Anti-bacterial Breath Mist]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPH 82 300 mg/day
Study: 9058219
Drug: Lidoflazine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidoflazine (1 mg/kg)
Study: 4037714
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of Primperan
Study: 31127399
Drug: Optimized formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized formulation of nifedipine (3.083 mg HPMC K15M, 29.859 mg HPMC E15LV, 3.541 mg Carbopol 974P)
Study: 31127399
Drug: Optimized formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized formulation of nifedipine
Study: 31240769
Drug: Symptom frequency
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom frequency (daily or weekly)
Study: 25213157
Drug: Recovery-focused cognitive-behavioural
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recovery-focused cognitive-behavioural therapy (CBT) plus treatment as usual (TAU)
Study: 23683793
Drug: Naltrexone 50
Normalized name: naltrexone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 50 mg/day + Guanfacine 1 mg/day (N/G)
Study: 23683793
Drug: Naltrexone 50
Normalized name: naltrexone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 50 mg/day + Guanfacine placebo (N/P)
Study: 23683793
Drug: Naltrexone placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone placebo + Guanfacine (P/G)
Study: 18971892
Drug: Magnet patch
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnet patch (M)
Study: 18971892
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch (P)
Study: 11002408
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (ALA; Tiobec) 600 mg per day for 20 days followed by 200 mg per day for 10 days
Study: 11002408
Drug: Cellulose starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellulose starch 100 mg per day as placebo
Study: 9216279
Drug: Warmed intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warmed intravenous fluid (W‐i.v.f.)
Study: 9216279
Drug: Room temperature
Normalized name: ROOM DEODORIZER POWDER MENTOR #3202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room temperature intravenous fluid (RT‐i.v.f.)
Study: 8484502
Drug: Ephedrine infusion
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ephedrine infusion (5 mg/min for the first 2 min, then 1 mg/min for the next 18 min)
Study: 8484502
Drug: Crystalloid administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crystalloid administration (15 mL/kg)
Study: 23901264
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + IFN‐α (3 million IU) 3 times per week (group B)
Study: 23901264
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + IFN‐γ (3 million IU) 3 times per week (group C)